Center for Immunity and Immunotherapies
Harnessing the Power of the Immune System
A drug derived from sea anemone venom demonstrates the potential to suppress inflammation without the severe side effects of existing therapies.
We’re partnering with companies to turn our discoveries into real-life advances that could transform pediatric health and well-being.
Engineering and Flow-Cytometric Analysis of Chimeric LAGLIDADG Homing Endonucleases from Homologous I-OnuI-Family Enzymes. Baxter SK, Scharenberg AM,Lambert AR. Methods Mol Biol. 2014;1123:191-221. doi: 10.1007/978-1-62703-968-0_14.
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Lebrec H, Molinier B, Boverhof D, Collinge M, Freebern W, Henson K, Mytych DT, Ochs HD, Wange R, Yang Y, Zhou L, Arrington J, Christin-Piché MS, Shenton J. Regul Toxicol Pharmacol. 2014 Feb 22. pii: S0273-2300 (14)00032-4. doi: 10.1016/j.yrtph.2014.02.008.
Suppressor of cytokine signaling 3 expression is diminished in sinonasal tissues from patients with chronic rhinosinusitis with nasal polyps. Hulse KE, Chaung K, Seshadri S, Suh L, Norton JE, Carter RG, Kern RC, Conley DB, Chandra RK, Tan BK, Peters AT, Grammer LC 3rd, Harris KE, Torgerson TR, Kato A, Schleimer RP. J Allergy Clin Immunol. 2014 Jan;133 (1):275-7.e1. doi: 10.1016/j.jaci.2013.08.015.
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH, Rawlings DJ. J Clin Invest. 2013 May 1;123 (5):2024-36. doi: 10.1172/JCI66963.
- Using Gene Therapy to Build an Immune System in Newborns Without One
8.28.18 – On the Pulse
Seattle Children’s recently opened a clinical trial that is seeking a potentially safer, less aggressive and equally effective path to a cure by using a novel gene therapy to fix the faulty gene that causes the most common type of severe combined immunodeficiency (SCID).
- Casebia Therapeutics Announces License and Collaboration Agreements With Seattle Children’s Research Institute
9.27.17 – Press Release
Casebia Therapeutics, a leading genetic engineering company, and Seattle Children’s Research Institute today announced an exclusive license agreement and research collaboration to explore new methods to treat and prevent autoimmune disease using CRISPR/Cas9 gene-edited regulatory T cells (Tregs) – a type of white blood cell that controls and modulates the body’s immune response.
- Seattle Children’s Researchers Pioneer Gene Editing that Kills, Resists HIV
9.30.15 – Seattle Children’s On the Pulse
Drs. David Rawlings and Andrew Scharenberg found that gene editing could be used to engineer T cells that resist HIV infection and kill HIV-infected T cells or B-cell tumors. The discovery could help scientists working toward cures for HIV, cancer and other diseases.